Erin Oliver

Erin Oliver has extensive work experience in the field of regulatory affairs, particularly in the pharmaceutical and healthcare industries. Erin is currently working as the Vice President of Regulatory Affairs, Rx to OTC Switch at Haleon since July 2022. Prior to this, Erin worked at GlaxoSmithKline Consumer Healthcare as a Regulatory Lead for Rx to OTC Switch from 2015 to August 2022. Erin also served as an Adjunct Professor at Fairleigh Dickinson University from 2014 to 2019. Earlier in their career, Erin held various roles at GSK Consumer Healthcare, including Lead of US Regulatory Affairs from 2012 to 2015. Erin also has an extensive tenure at GlaxoSmithKline Consumer Healthcare, where they worked as a Director/Senior Director of Global Regulatory Affairs from 2008 to 2013. Additionally, they held roles as an Associate Director of Regulatory Affairs from 2005 to 2008 and as a Regulatory Associate/Manager for OTC Products from 2001 to 2005. Erin's earlier experience includes working at BLOCK DRUG COMPANY as a Senior Development Scientist and CMC Regulatory Specialist from 1991 to 2001. Throughout their career, Erin has demonstrated expertise in developing global regulatory strategies, leading FDA meetings, negotiating with regulatory agencies, and ensuring compliance with postmarketing requirements.

Erin Oliver received a Bachelor of Science (B.S.) degree in Biology from Cook College. Erin then pursued a Master of Science (MS) in Pharmaceutical Sciences from Rutgers University. Later, they completed their Master of Business Administration (M.B.A.) from Cornell Johnson Graduate School of Management. Additionally, Erin obtained certifications such as the Women's Executive Leadership Program from Duquesne University Palumbo Donahue School of Business and became a Fellow of the Regulatory Affairs Professional Society (FRAPS). Erin also holds a membership in the Regulatory Affairs Certification Program (RAPS) and the Regulatory Affairs Professional Society (RAC).